Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia

被引:0
作者
Ren, Xinhua S. [1 ,2 ,3 ]
Herz, Lawrence [4 ,5 ]
Qian, Shirley [1 ,2 ,3 ]
Smith, Eric [1 ,4 ]
Kazis, Lewis E. [1 ,2 ,3 ]
机构
[1] Bedford Vet Affairs Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA
[2] Boston Univ, Sch Publ Hlth, CAPP, Boston, MA USA
[3] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA
[4] Boston Univ, Sch Med, Div Psychiat, Boston, MA 02118 USA
[5] Bedford VA Med Ctr, Bedford, MA USA
关键词
medication adherence; antipsychotic agents; schizophrenia; RESEARCH-TEAM PORT; ATYPICAL ANTIPSYCHOTICS; PHARMACY DATA; MEDICATIONS; HALOPERIDOL; RISPERIDONE; OLANZAPINE; EFFICACY; PATTERNS; PLACEBO;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The importance of medication adherence in sustaining control of schizophrenic symptoms has generated a great deal of interest in comparing levels of treatment adherence with different antipsychotic agents. However, the bulk of the research has yielded results that are often inconsistent. In this prospective, observational study, we assessed the measurement properties of 3 commonly used, pharmacy-based measures of treatment adherence with antipsychotic agents in schizophrenia using data from the Veterans Health Administration during 2000 to 2005. Patients were selected if they were on antipsychotics and diagnosed with schizophrenia (N = 18,425). A gap of >= 30 days (with no filled index medication) was used to define discontinuation of treatment as well as medication "episodes," or the number of times a patient returned to the same index agent after discontinuation of treatment within a 1-year period. The study found that the 3 existing measures differed in their approaches in measuring treatment adherence, suggesting that studies using these different measures would generate different levels of treatment adherence across antipsychotic agents. Considering the measurement problems associated with each existing approach, we offered a new, medication episode-specific approach, which would provide a fairer comparison of the levels of treatment adherence across different antipsychotic agents.
引用
收藏
页码:491 / 498
页数:8
相关论文
共 29 条
[1]  
Allison DB, 1999, AM J PSYCHIAT, V156, P1686
[2]   Optimal dosing of atypical antipsychotics in adults: A review of the current evidence. [J].
Citrome, L ;
Volavka, J .
HARVARD REVIEW OF PSYCHIATRY, 2002, 10 (05) :280-291
[3]   Enhancing medication compliance for people with serious mental illness [J].
Cramer, JA ;
Rosenheck, R .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 1999, 187 (01) :53-55
[4]  
Department of Veterans Affairs, 1998, CLIN GUID MAN PERS P
[5]   Antipsychotic maintenance in schizophrenia: Partial compliance and clinical outcome [J].
Docherty, J ;
Mahmoud, R ;
Grogg, A ;
Kozma, C .
SCHIZOPHRENIA RESEARCH, 2003, 60 (01) :281-282
[6]   Antipsychotic medication adherence: Is there a difference between typical and atypical agents? [J].
Dolder, CR ;
Lacro, JP ;
Dunn, LB ;
Jeste, DV .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (01) :103-108
[7]  
Haynes RB, 2001, AM HEART MONOGR S, P3
[8]  
Herz MI, 1997, AM J PSYCHIAT, V154, P1
[9]   A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia [J].
Hirsch, SR ;
Kissling, W ;
Bäuml, J ;
Power, A ;
O'Connor, R .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (06) :516-+
[10]   Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder [J].
Kane, JM ;
Carson, WH ;
Saha, AR ;
McQuade, RD ;
Ingenito, GG ;
Zimbroff, DL ;
Ali, MW .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (09) :763-771